Antiandrogen Monotherapy: Recommendations for the Treatment of Prostate Cancer

  title={Antiandrogen Monotherapy: Recommendations for the Treatment of Prostate Cancer},
  author={Alessandro Sciarra and Antonio Cardi and Franco di Silverio},
  journal={Urologia Internationalis},
  pages={91 - 98}
Objective: The concept of antiandrogens as monotherapy for the treatment of prostate cancer is discussed. Methods: Both Medline and Current Contents were used to identify studies on antiandrogen monotherapy in prostate cancer. We tried to analyze this database critically to estabilish whether or not there is evidence for using this monotherapy. Results: In particular, bicalutamide in monotherapy has been compared with castration in large international trials. Results show that antiandrogen… Expand
16 Citations
Objective: To detect the therapeutic efficacy of CPA and to compare it with surgical or medical castration in advanced prostate cancer Patients and Methods: Patients from 19 Urology Centers withExpand
Therapeutic Approach to Castration-resistant Prostate Cancer
The therapeutic options for treating prostate cancer once it has become hormone-refractory are reviewed, including: adrenal androgen inhibitors; antiandrogens; estrogens and progestins; and glucocorticoids. Expand
Overview of the latest treatments for castration-resistant prostate cancer
Four new agents have been shown to prolong overall survival in patients with CRPC in the postchemotherapy setting and Cabazitaxel is now considered the standard-of-care second-line chemotherapy for men with metastatic CRPC. Expand
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Predefined subgroup analyses showed that use of non-steroidal antiandrogen monotherapy, compared with castration, was less favourable for overall survival, clinical progression and treatment failure in men with metastatic disease. Expand
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study
Abiraterone is a well-tolerated and effective treatment modality for patients affected with metastatic castration-resistant prostate cancer and the drug has a better tolerability profile, gives significant pain relief, and increases the survival rate. Expand
Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer.
The current state of the literature regarding treatment modalities is reviewed, focusing on the treatment recommendations per the American Urological Association (AUA), recent clinical trials, and their limitations. Expand
Androgen deprivation therapy: a primer on concepts and therapeutic options
The surgical and medical options used to produce androgen blockade are reviewed, with bilateral orchiectomy being the historic gold standard with fewer side effects than medical castration, although currently less frequently utilized. Expand
Systemic treatment of prostate cancer and the role of radium-223
Prostate cancer is the most common malignancy in men, with 40,000 new diagnoses each year in the UK. This disease usually affects men aged 65 years and over, and there is a higher incidence andExpand
Current management of castrate-resistant prostate cancer.
This review discusses the various currently available treatments for patients with castrate-resistant PCa, from secondary hormonal manipulations to options for post-docetaxel systemic therapy. Expand
Safety and tolerability of intermittent androgen deprivation therapy: A literature review
  • D. Gruca, P. Bacher, U. Tunn
  • Medicine
  • International journal of urology : official journal of the Japanese Urological Association
  • 2012
Benefits for intermittent androgen deprivation therapy were observed for the short‐term side‐effects mainly during the off‐treatment phase, whereas the data for the long-term side-effects were not as conclusive, and quality of life evaluations are more in support of intermittent androgens deprivation therapy. Expand


A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.
A comparison of pharmacologic effects showed that only the incidence of hot flushes was lower in the bicalutamide group, whereas breast tenderness and gynecomastia were more common, which translated into better quality of life during the first several months with regard to sexual relations and sexual functioning. Expand
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
PURPOSE Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in whichExpand
Quality of Life Issues Relating to Endocrine Treatment Options
Data from two large studies of bicalutamide monotherapy show that this non-steroidal antiandrogen is associated with significant health-related quality of life advantages in the treatment of patients with locally advanced (M0) disease compared with castration, suggesting that this treatment may benefit patients with early disease. Expand
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Bicalutamide monotherapy yielded comparable results relative to standard treatment with MAB, induced fewer side effects, and produced a better QOL. Expand
The bicalutamide Early Prostate Cancer Program. Demography.
This is the largest randomized clinical trial program to date in local prostate cancer and is expected to provide critical information on the role of bicalutamide as an addition to standard care for patients with local prostate cancers who have received a therapy of curative intent or are candidates for watchful waiting. Expand
Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
The results indicate that nilutamide as a single agent has an acceptable toxicity and a moderate activity, and may maintain sexual interest in a discrete number of cases, and whether monotherapy with nonsteroidal antiandrogens offers a valid option in the palliation of advanced disease remains to be seen in comparative prospective trials. Expand
Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
It is shown that in spite of a constant elevation of serum testosterone (25% over baseline) flutamide 250 mg tid may be a reasonable alternative to castraction in highly selected patients with well to moderatly differentiated low volume metastatic prostate cancer and wishing to avoid the side effects of androgen deprivation. Expand
Orchidectomy following Failure of Antiandrogen Monotherapy in Patients with Metastatic Prostate Cancer
Patients with metastatic prostate cancer who are initially treated by oral antiandrogens and then have progressive disease may be offered surgical castration as a second–line treatment following relapse on antiandrogen monotherapy are reviewed. Expand
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
Bicalutamide 150-mg monotherapy provides a similar survival outcome to castration in previously untreated patients with nonmetastatic advanced prostate cancer and confers statistically significant benefits over castration with respect to sexual interest and physical capacity. Expand
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
Bicalutamide 150 mg daily as immediate therapy, alone or as adjuvant to treatment of curative intent, significantly reduced the risk of disease progression in patients with localized or locally advanced prostate cancer. Expand